Response to Letter to the Editor "Zink TK. Vaccine 2007;25(15):2766-7"

Vaccine

Volumn 25, Issue 42, 2007, Pages 7285-7287

  Gorse, Geoffrey J ^a   Keitel, Wendy ^b   Keyserling, Harry ^c   Taylor, David N ^d   Lock, Michael ^e   Alves, Katia ^e   Kenner, Julie ^e   Deans, Lynne ^e   Gurwith, Marc ^e  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d VaxInnate Corporation   (United States)

^e VaxGen Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRAX VACCINE; RPA 102; UNCLASSIFIED DRUG;

ANTIBODY RESPONSE; CLINICAL RESEARCH; CLINICAL TRIAL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FOLLOW UP; HUMAN; IMMUNE RESPONSE; LETTER; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SEX DIFFERENCE; UNSPECIFIED SIDE EFFECT;

ANTHRAX VACCINES; FEMALE; HUMANS; MALE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SAFETY; VACCINES, SYNTHETIC;

EID: 34748903009     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.08.010     Document Type: Letter

References (18)

1. Zink T.K. Letter to the Editor: Gorse GJ, et al. "Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA102) anthrax vaccine: A randomized, double-blinded, controlled, multicenter trial" [Vaccine 24 (2006) 5950-5959]. Vaccine 25 (2007) 2766-2767
2. Gorse G.J., Keitel W., Keyserling H., Taylor D.N., Lock M., Alves K., et al. Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA102) anthrax vaccine: a randomized, double-blinded, controlled, multicenter trial. Vaccine 24 (2006) 5950-5959
3. Pittman P.R. Aluminum-containing vaccine associated adverse events: role of route of administration and gender. Vaccine 20 (2002) S48-S50
4. Pittman P.R., Kim-Ahn G., Pifat D.Y., Coonan K., Gibbs P., Little S., et al. Anthrax vaccine: immunogenicity and safety of a dose-reduction, route-change comparison study in humans. Vaccine 20 (2002) 1412-1420
5. Epidemiology & prevention of vaccine-preventable diseases. The pink book ([http://www.cdc.gov/nip/publications/pink/anthrax.pdf] accessed 4/16/07).
6. Joellenbeck L., Zwanziger L., Durch J., and Strom B. The anthrax vaccine is it safe? Does it work?. 2nd ed. (2002), National Academy Press, Washington, DC
7. Geier M.R., and Geier D.A. Anthrax immunization and joint related adverse reactions in light of biological warfare scenarios. Clin Exp Rheumatol 20 (2002) 217-220
8. Shah C., Lemke S., Singh V., and Gentile T. Case reports of aplastic anemia after vaccine administration. Am J Hematol 77 (2004) 204
9. Geier M.R., and Geier D.A. Gastrointestinal adverse reactions following anthrax vaccination: an analysis of the vaccine adverse events reporting system (VAERS) database. Hepatogastroenterology 51 (2004) 762-767
10. Mahan C.M., Kang H.K., Dalager N.A., and Heller J.M. Anthrax vaccination and self-reported symptoms, functional status, and medical conditions in the National Health Survey of Gulf War Era Veterans and their Families. Ann Epidemiol 14 2 (2004) 81-88
11. Muellenhoff M., Cukrowski T., Morgan M., and Dorton D. Oral pemphigus vulgaris after anthrax vaccine administration: association or coincidence?. J Am Acad Dermatol 50 (2004) 136-139
12. Vasudev M., and Zacharisen M.C. New-onset rheumatoid arthritis after anthrax vaccination. Ann Allergy Asthma Immunol 97 (2006) 110-112
13. Stolberg SG, Miller J. A nation challenged: anthrax prevention; researchers call anthrax vaccine safe and likely to work. New York Times. March 7, 2002. Available at http://query.nytimes.com/gst/fullpage.html?sec=health&res=950CE7DA1230F934A35750C0A9649C8B63. Accessed August 24, 2007.
14. McNeil DG Jr. A death may be related to vaccines. New York Times. November 19, 2003. Available at http://query.nytimes.com/gst/fullpage .html?sec=health&res=9505E6D61F38F93AA25752C1A9659 C8B63. Accessed August 24, 2007.
15. Goldstein D. Anthrax vaccine under fire; troops speak out; refusal rate concerns military. The Kansas City Star July (2005) A1
16. Biological products, bacterial vaccines and toxoids, implementation of efficacy review, anthrax vaccine adsorbed. Final order, 70 F.R. 75180-98.
17. Sever J.L., Brenner A.L., Gale A.D., Lyle J.M., Moulton L.H., Ward B.J., et al. Safety of anthrax vaccine: an expanded review and evaluation of adverse events reported to the vaccine adverse event reporting system (VAERS). Pharmacoepidemiol Drug Saf 13 (2004) 825-840
18. Zhou W, Pool V, Iskander JK, English-Bullard R, Ball R, Wise RP, et al. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)-United States, 1991-2001. MMWR Surveill Summ. 2003 Jan 24;52(1):1-24. Erratum in: MMWR Morb Mortal Wkly Rep. 2003 Feb 14;52(06):113.